{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa%2C+Junctional",
    "query": {
      "condition": "Epidermolysis Bullosa, Junctional"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Epidermolysis+Bullosa%2C+Junctional&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T16:51:44.220Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02670330",
      "title": "Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101-6.0 cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 152,
      "start_date": "2015-06-09",
      "completion_date": "2018-09-03",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02670330"
    },
    {
      "nct_id": "NCT02384460",
      "title": "ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101-6.0 cream",
          "type": "DRUG"
        },
        {
          "name": "Placebo (SD-101-0.0) cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Month and older"
      },
      "enrollment_count": 169,
      "start_date": "2015-03-11",
      "completion_date": "2017-07-05",
      "has_results": true,
      "last_update_posted_date": "2020-04-09",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 21,
      "location_summary": "Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02384460"
    },
    {
      "nct_id": "NCT00587223",
      "title": "Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Apligraf",
          "type": "DEVICE"
        },
        {
          "name": "Standard dressing regimen",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Organogenesis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-12",
      "completion_date": "2008-12",
      "has_results": true,
      "last_update_posted_date": "2010-06-29",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 5,
      "location_summary": "Stanford, California • Miami, Florida • New York, New York + 2 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00587223"
    },
    {
      "nct_id": "NCT02090283",
      "title": "Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101 dermal cream (6%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 42,
      "start_date": "2014-03-26",
      "completion_date": "2018-09-14",
      "has_results": true,
      "last_update_posted_date": "2019-11-04",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02090283"
    },
    {
      "nct_id": "NCT05533866",
      "title": "Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "APR-TD011",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 15,
      "start_date": "2023-02-06",
      "completion_date": "2025-03-31",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533866"
    },
    {
      "nct_id": "NCT02014376",
      "title": "Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "SD-101 dermal cream (3%)",
          "type": "DRUG"
        },
        {
          "name": "SD-101 Dermal Cream (6%)",
          "type": "DRUG"
        },
        {
          "name": "Vehicle (SD-101 0%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scioderm, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 48,
      "start_date": "2014-01-06",
      "completion_date": "2014-06-24",
      "has_results": true,
      "last_update_posted_date": "2020-01-13",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014376"
    },
    {
      "nct_id": "NCT03472287",
      "title": "To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epidermolysis Bullosa (EB)",
        "Epidermolysis Bullosa Simplex",
        "Dystrophic Epidermolysis Bullosa",
        "Junctional Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Diacerein 1% Ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Castle Creek Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2018-05-18",
      "completion_date": "2019-02-14",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03472287"
    },
    {
      "nct_id": "NCT03526159",
      "title": "Gentamicin for Junctional Epidermolysis Bullosa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Junctional Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "Gentamicin Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 6,
      "start_date": "2018-06-01",
      "completion_date": "2020-08-31",
      "has_results": false,
      "last_update_posted_date": "2020-04-07",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526159"
    },
    {
      "nct_id": "NCT03578029",
      "title": "Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Junctional Epidermolysis Bullosa",
        "Dystrophic Epidermolysis Bullosa"
      ],
      "interventions": [
        {
          "name": "RGN-137",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lenus Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-05-22",
      "completion_date": "2021-11-23",
      "has_results": false,
      "last_update_posted_date": "2022-08-22",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 5,
      "location_summary": "Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03578029"
    },
    {
      "nct_id": "NCT03269474",
      "title": "Computational Drug Repurposing for All EBS Cases",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Epidermolysis Bullosa",
        "Healthy",
        "Genetic Skin Disease",
        "Epidermolysis Bullosa Simplex",
        "Epidermolysis Bullosa, Junctional",
        "Epidermolysis Bullosa Dystrophica"
      ],
      "interventions": [
        {
          "name": "Experimental Group",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Joyce Teng",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2017-11-28",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-07-23T16:51:44.220Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03269474"
    }
  ]
}